Stealth BioTherapeutics Corp (Nasdaq: MITO) is up more than 50% on FDA approval.

Stealth BioTherapeutics Corp (Nasdaq: MITO) is up more than 50% on FDA approval.

BOSTON, May 12, 2022 /PRNewswire/ — Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today that the US Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation to elamipretide for the treatment of patients with Duchenne muscular dystrophy (DMD)

Read the entire article here.

https://www.prnewswire.com/news-releases/stealth-biotherapeutics-receives-orphan-drug-designation-from-fda-for-elamipretide-for-treatment-of-duchenne-muscular-dystrophy-301545679.html

 

JOIN OUR NEWSLETTER

Signup today for free and be the first to get notified of breaking news.

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist